IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.
Institutional and Insider Ownership
87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 25.0% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares IDEXX Laboratories and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEXX Laboratories | 25.03% | 71.96% | 33.60% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEXX Laboratories | $4.55 billion | 8.73 | $1.06 billion | $14.22 | 35.49 |
| InspireMD | $10.84 million | 3.39 | -$19.92 million | ($0.64) | -1.23 |
IDEXX Laboratories has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for IDEXX Laboratories and InspireMD, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEXX Laboratories | 0 | 4 | 6 | 0 | 2.60 |
| InspireMD | 0 | 0 | 3 | 0 | 3.00 |
IDEXX Laboratories currently has a consensus target price of $747.00, indicating a potential upside of 48.01%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 469.69%. Given InspireMD’s stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than IDEXX Laboratories.
Risk & Volatility
IDEXX Laboratories has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Summary
IDEXX Laboratories beats InspireMD on 11 of the 14 factors compared between the two stocks.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
